Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Cost of RevenueGross ProfitLeasesOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsReceivables - NetReceivables - OtherShares IssuedShares OutstandingShares Outstanding
Ratios

RedHill Biopharma (RDHL) Gross Profit (2016 - 2023)

RedHill Biopharma has reported Gross Profit over the past 9 years, most recently at $990000.0 for Q2 2023.

  • Quarterly Gross Profit fell 89.41% to $990000.0 in Q2 2023 from the year-ago period, while the trailing twelve-month figure was $15.3 million through Jun 2023, down 51.16% year-over-year, with the annual reading at $5.5 million for FY2025, 13.67% up from the prior year.
  • Gross Profit was $990000.0 for Q2 2023 at RedHill Biopharma, down from $2.0 million in the prior quarter.
  • Over five years, Gross Profit peaked at $12.4 million in Q3 2021 and troughed at -$659000.0 in Q1 2020.
  • The 5-year median for Gross Profit is $5.5 million (2020), against an average of $5.5 million.
  • Year-over-year, Gross Profit plummeted 149.92% in 2020 and then soared 1666.31% in 2021.
  • A 5-year view of Gross Profit shows it stood at $802000.0 in 2019, then soared by 1247.76% to $10.8 million in 2020, then tumbled by 74.68% to $2.7 million in 2021, then skyrocketed by 53.45% to $4.2 million in 2022, then crashed by 76.43% to $990000.0 in 2023.
  • Per Business Quant, the three most recent readings for RDHL's Gross Profit are $990000.0 (Q2 2023), $2.0 million (Q1 2023), and $4.2 million (Q4 2022).